| Literature DB >> 35745206 |
Grażyna Budryn1, Iwona Majak1, Joanna Grzelczyk1, Dominik Szwajgier2, Alejandro Rodríguez-Martínez3, Horacio Pérez-Sánchez3.
Abstract
One of the symptoms of Alzheimer's disease (AD) is low acetylcholine level due to high acetylcholinesterase (AChE) activity. For this reason, AChE inhibitors are used in the treatment of AD, the prolonged use of which may cause a cholinergic crisis. There is a need to search for safe natural AChE inhibitors. The study analyzed 16 hydroxybenzoic acids using calorimetry and docking simulation as AChE inhibitors. All tested compounds were shown to inhibit the hydrolysis of ACh. The best properties were shown by methyl syringinate, which acted as competitive inhibitor at a catalytic site. The tested compounds also interacted with the anionic or peripheral binding site known to block β-amyloid plaques formation. The activity of the tested hydroxybenzoic acids IC50 ranged from 5.50 to 34.19 µmol/µmol of AChE, and the binding constant Ka from 20.53 to 253.16 L/mol, which proves their reversible, non-toxic effect, and activity at physiological concentrations.Entities:
Keywords: Alzheimer disease; ITC; acetylcholinesterase; docking simulation; hydroxybenzoic acids
Mesh:
Substances:
Year: 2022 PMID: 35745206 PMCID: PMC9227119 DOI: 10.3390/nu14122476
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 6.706
Figure 1ITC raw data (a) ACh hydrolysis catalyzed by AChE; (b) ACh hydrolysis catalyzed by AChE in the presence of methyl syringate; (c) AChE titrated with methyl syringate.
Anti-AChE activity studied by ITC method and comparison with colorimetric method results. * Reprinted/adapted with permission from Refs. [23,24,25]. 2022, Dominik Szwajgiwer.
| Compound | Abbreviation | Inhibitory Activity | |||
|---|---|---|---|---|---|
| ITC | Ellman’s Assay | ||||
| % Inhibition | IC50 | Ka × 103 (L/mol) | |||
| methyl syringate | MS | 90.93 ± 7.13 | 5.50 ± 0.43 | 154.32 ± 11.12 | 9.1 ±1.6 |
| 4-hydroxyphenylpyruvic acid | x | 84.93 ± 5.82 | 5.89 ± 0.40 | 253.16 ± 14.53 | 23.6 ± 1.5 |
| salicylic acid | SA | 82.30 ± 4.77 | 6.07 ± 0.35 | 51.55 ± 3.77 | 11.8 ± 0.4 |
| 4-hydroxyphenylacetic acid | 4-OH-PA | 80.20 ± 8.04 | 6.24 ± 0.63 | 66.23 ± 5.46 | NA |
| 4-hydroxybenzoic acid | 4-OH-BA | 78.60 ± 8.30 | 6.36 ± 0.67 | 58.48 ± 7.81 | 3.7 ± 0.3 |
| homovanillic acid | HVA | 77.50 ± 2.59 | 6.45 ± 0.22 | 136.05 ± 5.44 | 21.8 ± 0.4 |
| nordihydroguaiaretic acid | NDGA | 77.20 ± 4.84 | 6.47 ± 0.41 | 57.80 ± 4.26 | 37.3 ± 1.2 |
| protocatechuic acid | PCA | 77.15 ± 5.16 | 6.50 ± 0.43 | 57.63 ± 2.58 | NA |
| 3-hydroxybenzoic acid | 3-OH-BA | 74.80 ± 8.63 | 6.68 ± 0.77 | 64.10 ± 6.04 | 2.6 ± 0.1 |
| vanillic acid | VA | 73.70 ± 1.90 | 6.79 ± 0.18 | 52.36 ± 2.53 | 3.2 ± 0.0 |
| syringic acid | SRA | 71.80 ± 3.12 | 6.96 ± 0.30 | 183.15 ± 6.69 | 5.4 ± 0.1 |
| homogentisic acid | HGA | 68.78 ± 0.88 | 7.16 ± 0.09 | 116.92 ± 2.05 | 9.6 ± 2.4 |
| gentisic acid | GNA | 62.38 ± 6.39 | 8.02 ± 0.82 | 76.92 ± 8.78 | 68.6 ± 0.7 |
| gallic acid | GA | 53.70 ± 2.86 | 9.32 ± 0.50 | 51.55 ± 3.57 | 3.8 ± 0.1 |
| ethyl 4-hydroxybenzoate | E-4-OH-BA | 15.93 ± 0.75 | 31.38 ± 1.48 | 20.53 ± 1.79 | 28.1 ± 0.1 |
| ethyl vanillate | EV | 14.60 ± 2.33 | 34.19 ± 5.46 | 38.76 ± 5.91 | 33.5 ± 2.5 |
Figure 2At (a–p) results of docking simulation. On the top left: a 2D model of the ligand interaction (name in the graph) with AChE; from below: the energy values of the interactions that make up the total binding energy of the ligand with AChE; on the top right: energetic values of the AChE interactions to individual ligand atoms; from below: the total binding energy of the ligand to the most significant interacting AChE amino acid residues.